Literature DB >> 3793265

Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo-oligosaccharides.

J Van Rinsum, L A Smets, H Van Rooy, D H Van den Eijnden.   

Abstract

We have tried to identify carbohydrate structures involved in recognition and/or lysis of K562 target cells by human natural killer (NK) cells. Inhibition studies were performed with mono-, di- and trisaccharides, and with glycopeptides and glycoproteins of known carbohydrate composition. When tested with various monosaccharides, lysis of K562 cells was inhibited only by N-acetylneuraminic acid (NeuAc). Di- and trisaccharides and glycopeptides containing NeuAc or N-glycolylneuraminic acid (NeuGc) all inhibited NK cell-mediated lysis. Among the non-sialylated carbohydrates tested, only Gal beta(1----3)GalNAcol was effective. The inhibitory capacity of sialylated compounds appeared to be dependent on the linkage type of the sialic acid residue; carbohydrates containing alpha(2----6)-linked sialic acids were more potent inhibitors than their alpha(2----3) isomers. Also the sugar to which the sialic acid residue was attached was of importance, NeuAc alpha(2----6)GalNAcol being more effective than NeuAc alpha(2----6)Gal beta 1----R (where R = glucose or oligosaccharide-peptide). Sialylated compounds and free sialic acid had minor or no effects on cell-mediated cytotoxicity by allo-sensitized cytotoxic T lymphocytes. The conjugation of target cells and NK effector cells was not inhibited by carbohydrates that effectively blocked the cytolytic response. These results may indicate that cell-surface carbohydrates containing alpha(2----6)-linked sialic acid are crucial structures in a post-binding event in NK-cell-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3793265     DOI: 10.1002/ijc.2910380620

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Clustered carbohydrates as a target for natural killer cells: a model system.

Authors:  Elena I Kovalenko; Elena Abakushina; William Telford; Veena Kapoor; Elena Korchagina; Sergei Khaidukov; Irina Molotkovskaya; Alexander Sapozhnikov; Pavel Vlaskin; Nicolai Bovin
Journal:  Histochem Cell Biol       Date:  2007-01-17       Impact factor: 4.304

2.  Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Authors:  Shadi Ferdosi; Douglas S Rehder; Paul Maranian; Erik P Castle; Thai H Ho; Harvey I Pass; Daniel W Cramer; Karen S Anderson; Lei Fu; David E C Cole; Tao Le; Xifeng Wu; Chad R Borges
Journal:  J Proteome Res       Date:  2017-11-21       Impact factor: 4.466

Review 3.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

4.  Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma.

Authors:  K N Syrigos; I Fyssas; M M Konstandoulakis; K J Harrington; S Papadopoulos; N Milingos; P Peveretos; B C Golematis
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

5.  Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.

Authors:  T Hamada; S Matsukita; M Goto; S Kitajima; S K Batra; T Irimura; K Sueyoshi; K Sugihara; S Yonezawa
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 6.  A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer.

Authors:  Lenneke A M Cornelissen; Sandra J Van Vliet
Journal:  Biomolecules       Date:  2016-05-03

7.  Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.

Authors:  Jason E Hudak; Stephen M Canham; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2013-11-24       Impact factor: 15.040

8.  A novel monoclonal antibody specific for sialylated MUC1 mucin.

Authors:  M Yamamoto; V P Bhavanandan; S Nakamori; T Irimura
Journal:  Jpn J Cancer Res       Date:  1996-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.